Kymab Ltd | Home
             
Pause Play
Kymab secures US$40 million investment from two of the largest foundations in the world.
Kymab announces publication of the Kymouse Technology in Nature Biotechnology.
Kymab initiates vaccine research in collaboration with The Bill & Melinda Gates Foundation.
Kymab Access enables academics to pursue the discovery and development of novel antibody therapeutics.
Kymab appoints Dr Christian Grøndahl as Chief Executive Officer and Dr David Chiswell as Chairman.
Kymab secures US$40 million investment from two of the largest foundations in the world.
Kymab announces publication of the Kymouse Technology in Nature Biotechnology.
Kymab initiates vaccine research in collaboration with The Bill & Melinda Gates Foundation.
Kymab Access enables academics to pursue the discovery and development of novel antibody therapeutics.
Kymab appoints Dr Christian Grøndahl as Chief Executive Officer and Dr David Chiswell as Chairman.
Kymab secures US$40 million investment from two of the largest foundations in the world.
Kymab announces publication of the Kymouse Technology in Nature Biotechnology.
Kymab initiates vaccine research in collaboration with The Bill & Melinda Gates Foundation.
Kymab Access enables academics to pursue the discovery and development of novel antibody therapeutics.
Kymab appoints Dr Christian Grøndahl as Chief Executive Officer and Dr David Chiswell as Chairman.

Advanced therapeutic antibody discovery & development

Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering transgenic mouse platform. We are building a rich pipeline of assets in 3 therapeutic spaces: immuno-oncology, immunology and opportunistic.

Perfecting discovery

Kymouse™ is transforming the discovery of very high affinity fully human monoclonal antibodies against a broad range of drug targets and has been designed to overcome the limitations of previous humanised transgenic antibody platforms.

Partnering

Kymab discovers and develops its drugs both independently and in collaboration with pharmaceutical, biotechnology and academic partners. We are employing our proprietary technologies, including Kymouse™ to discover, develop and commercialise monoclonal antibody medicines to difficult and novel drug targets.

News

Events

12-15/01/2015
JP Morgan Healthcare Conference
San Francisco, USA
8-13/02/2015
Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
Banff, Canada